Nucleoside transporter proteins

Area of Science:

• Molecular Biology
• Pharmacology
• Cell Biology

Background:

• Concentrative nucleoside transporters (CNT; SLC28) and equilibrative nucleoside transporters (ENT; SLC29) are key membrane proteins involved in nucleoside transport.
• These transporters exhibit distinct substrate selectivity and energy requirements, with varied tissue distribution and regulated expression.
• Their localization in epithelial cells facilitates vectorial flux of nucleosides and nucleoside-derived drugs.

Purpose of the Study:

• To review the physiological and clinical significance of CNT and ENT.
• To highlight their roles in nucleoside homeostasis, adenosine signaling, and drug transport.
• To discuss the impact of transporter polymorphisms on drug efficacy and pharmacokinetics.

Main Methods:

• Literature review of studies on nucleoside transporters (SLC28 and SLC29).
• Analysis of transporter expression, localization, and function.
• Examination of clinical implications in cancer therapy and cardiovascular diseases.

Main Results:

• CNT and ENT families comprise three and four members, respectively.
• Nucleoside transporters modulate extracellular adenosine levels and are essential for nucleoside-based chemotherapy drug uptake.
• ENTs are targets for vasodilatory drugs, and transporter polymorphisms can influence drug cytotoxicity and pharmacokinetics.

Conclusions:

• Nucleoside transporters play critical roles in both physiological processes and clinical applications, particularly in cancer chemotherapy and cardiovascular drug action.
• Understanding transporter characteristics and polymorphisms is vital for optimizing nucleoside-based therapies and drug development.
• Further research into nucleoside transporter function and regulation can lead to improved therapeutic strategies.